Literature DB >> 15892293

Spread of T lymphocyte immune responses to myelin epitopes with duration of multiple sclerosis.

Selina Davies1, Tim Nicholson, Matilde Laura, Gavin Giovannoni, Daniel M Altmann.   

Abstract

Although the primary cause of multiple sclerosis (MS) is unclear, evidence supports a role for autoimmune attack of myelin by T lymphocytes. However, it has been difficult to relate patterns of autoimmunity to pathogenesis. In mouse models, the case has been made for relapsing and remitting disease driven by epitope spread: an initial lesion leads to presentation of central nervous system antigens, in turn triggering the next wave of autoimmune T cells of different specificity, the response thus broadening. Few studies have been done to determine whether these events could be important over the longer time scale of human disease. We compared T cell responses with a panel of myelin epitopes in clinically isolated syndrome patients with a first attack, patients with MS with a mean disease duration of 0.95 years, and patients with MS having a mean disease duration of 15.9 years. T cells from patients with long-term disease recognize more myelin epitopes than patients with recent-onset disease. The epitope myelin basic protein 131-149, in particular, was more commonly recognized by patients with long-term disease. The data support the notion that the T cell response in MS broadens with time and is thus implicated in the ongoing pathogenic process. However, there was no clear correlation between disease severity and number of epitopes recognized. This may argue against a simple causal role of epitope spread in driving progression, as has been suggested in experimental allergic encephalomyelitis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15892293     DOI: 10.1093/jnen/64.5.371

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  8 in total

1.  Role of pathogenic T cells and autoantibodies in relapse and progression of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in LEW.1AV1 rats.

Authors:  Yoh Matsumoto; Il-Kwon Park; Keiko Hiraki; Shin Ohtani; Kuniko Kohyama
Journal:  Immunology       Date:  2008-10-29       Impact factor: 7.397

2.  Aquaporin-4-antibody-positive Neuromyelitis Optica Spectrum Disorder in a Patient with Charcot-Marie-Tooth Disease Type 1A.

Authors:  Yuichi Hamada; Kazusa Takahashi; Takamichi Kanbayashi; Yuki Hatanaka; Shunsuke Kobayashi; Masahiro Sonoo
Journal:  Intern Med       Date:  2020-12-22       Impact factor: 1.271

3.  MS in South Asians in England: early disease onset and novel pattern of myelin autoimmunity.

Authors:  Richard S Nicholas; Vassiliki Kostadima; Maya Hanspal; Benjamin R Wakerley; Ruhena Sergeant; Saskia Decuypere; Omar Malik; Rosemary J Boyton; Daniel M Altmann
Journal:  BMC Neurol       Date:  2015-05-03       Impact factor: 2.474

4.  HLA Class II Genotype Does Not Affect the Myelin Responsiveness of Multiple Sclerosis Patients.

Authors:  Judith Derdelinckx; Irene Nkansah; Naomi Ooms; Laura Van Bruggen; Marie-Paule Emonds; Liesbeth Daniëls; Tatjana Reynders; Barbara Willekens; Patrick Cras; Zwi N Berneman; Nathalie Cools
Journal:  Cells       Date:  2020-12-17       Impact factor: 6.600

5.  Pro-inflammatory dopamine-2 receptor-specific T cells in paediatric movement and psychiatric disorders.

Authors:  Deepti Pilli; Alicia Zou; Ruebena Dawes; Joseph A Lopez; Fiona Tea; Ganesha Liyanage; Fiona Xz Lee; Vera Merheb; Samuel D Houston; Aleha Pillay; Hannah F Jones; Sudarshini Ramanathan; Shekeeb Mohammad; Anthony D Kelleher; Stephen I Alexander; Russell C Dale; Fabienne Brilot
Journal:  Clin Transl Immunology       Date:  2020-12-17

Review 6.  Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure.

Authors:  Navid Manouchehri; Victor H Salinas; Negar Rabi Yeganeh; David Pitt; Rehana Z Hussain; Olaf Stuve
Journal:  Front Neurol       Date:  2022-03-31       Impact factor: 4.003

Review 7.  Inflammatory demyelinating diseases of the central nervous system.

Authors:  Romana Höftberger; Hans Lassmann
Journal:  Handb Clin Neurol       Date:  2017

Review 8.  Recent advances in understanding multiple sclerosis.

Authors:  Peter K Stys; Shigeki Tsutsui
Journal:  F1000Res       Date:  2019-12-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.